{"organizations": [], "uuid": "6cb9b75b387c4ea8df2ac985cbac8cf4a0a8c02c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/2", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/08/pr-newswire-nevro-to-report-operating-results-for-the-fourth-quarter-and-full-year-2017.html", "country": "US", "domain_rank": 767, "title": "Nevro to Report Operating Results for the Fourth Quarter and Full Year 2017", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-09T00:35:00.000+02:00", "replies_count": 0, "uuid": "6cb9b75b387c4ea8df2ac985cbac8cf4a0a8c02c"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/08/pr-newswire-nevro-to-report-operating-results-for-the-fourth-quarter-and-full-year-2017.html", "ord_in_thread": 0, "title": "Nevro to Report Operating Results for the Fourth Quarter and Full Year 2017", "locations": [], "entities": {"persons": [], "locations": [{"name": "redwood city", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}, {"name": "redwood city", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}, {"name": "nevro", "sentiment": "none"}, {"name": "california", "sentiment": "none"}], "organizations": [{"name": "nevro corp.", "sentiment": "negative"}, {"name": "nyse", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "REDWOOD CITY, Calif., Feb. 8, 2018 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it will release financial results and full year of 2017 after market close on Thursday, February 22, 2018. Company management will host a conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Thursday, February 22, 2018.\nInvestors interested in listening to the conference call may do so by dialing (866) 393-4306 for U.S. callers, or (734) 385-2616 for international callers (Conference ID: 2584428), or from the webcast on the \"Investors\" section of the Company's website at www.nevro.com/investors . Following the call, a replay will be available on the Investor Events and Presentations webpage of the Company's website.\nAbout Nevro\nHeadquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the SENZA® spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The SENZA® system is the only SCS system that delivers Nevro's proprietary HF10™ therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro.\nInvestor Relations Contact:\nNevro Investor Relations\nKatherine Bock\n(650) 433-3247\nir@nevro.com\nView original content with multimedia: http://www.prnewswire.com/news-releases/nevro-to-report-operating-results-for-the-fourth-quarter-and-full-year-2017-300595910.html\nSOURCE Nevro Corp.", "external_links": ["http://www.prnewswire.com/news-releases/nevro-to-report-operating-results-for-the-fourth-quarter-and-full-year-2017-300595910.html", "http://www.nevro.com/investors"], "published": "2018-02-09T00:35:00.000+02:00", "crawled": "2018-02-09T01:03:26.026+02:00", "highlightTitle": ""}